Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 121-143 , March 2006

Environmental oestrogens, cosmetics and breast cancer

  • P.D. Darbre, BSc, PhD (Senior Lecturer in Oncology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 118 987 5123x7035/7025; fax: +44 118 931 0180.

References 

  1. Neville MC, editor. Journal of Mammary Gland Biology and Neoplasia volume 1 (1996) – volume 10. Kluwer Academic Publishers; 2005.
  2. Lipworth L. Epidemiology of breast cancer. European Journal of Cancer Prevention. 1995;4:7–30
  3. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The Lancet Oncology. 2001;2:133–140
  4. Darbre PD. Recorded quadrant incidence of female breast cancer in Great Britain suggests a disproportionate increase in the upper outer quadrant of the breast. Anticancer Research. 2005;25:2543–2550
  5. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiology Biomarkers and Prevention. 2005;14:20–26
  6. Darbre PD. Underarm cosmetics and breast cancer. Journal of Applied Toxicology. 2003;23:89–95
  7. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science. 2004;95:866–871
  8. Miller WR. Estrogen and Breast Cancer. London: Chapman Hall; 1996;
  9. Pasqualini JR, Katzenellenbogen BS. Hormone-Dependent Cancer. New York, NY: Marcel Dekker; 1996;
  10. Lonning PE, editor. Endocrinology and treatment of breast cancer. Clinics in Endocrinology and Metabolism 2004;18:1–130.
  11. Davis DL, Axelrod D, Bailey L, et al. Rethinking breast cancer risk and the environment: the case for the precautionary principle. Environmental Health Perspectives. 1998;106:523–529
  12. Fernandez MF, Pedraza V, Olea N. Estrogens in the environment: is there a breast cancer connection?. The Cancer Journal. 1998;11:11–17
  13. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin. Environmental Health Perspectives. 2001;109:35–47
  14. Wolff MS, Britton JA, Wilson VP. Environmental risk factors for breast cancer among African–American women. Cancer. 2003;97(supplement 1):289–310
  15. Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environmental Health Perspectives. 2003;111:1007–1019
  16. Darbre PD. Underarm cosmetics are a cause of breast cancer. European Journal of Cancer Prevention. 2001;10:389–393
  17. Harvey PW, Darbre P. Endocrine disrupters and human health: could oestrogenic chemicals in bodycare cosmetics adversely affect breast cancer incidence in women? A review of evidence and call for further research. Journal of Applied Toxicology. 2004;24:167–176
  18. Matthiessen P. Historical perspective on endocrine disruption in wildlife. Pure and Applied Chemistry. 2003;71:2197–2206
  19. Russo J, Russo IH. Biology of disease. Biological and molecular bases of mammary carcinogenesis. Laboratory Investigation. 1987;57:112–137
  20. Tokunaga M, Norman JE, Asano M, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. Journal of the National Cancer Institute. 1979;62:1347–1359
  21. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–1727
  22. Beral V. Million women study collaborators. Breast cancer and hormone replacement in the million women study. Lancet. 2003;362:419–427
  23. Woods HF (Chairman). Phytoestrogens and Health. Crown copyright; 2002.
  24. Matsumura A, Ghosh A, Pope GS, Darbre PD. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 2005;94:431–443
  25. Bouker KB, Hilakivi-Clarke L. Genistein: Does it prevent or promote breast cancer?. Environmental Health Perspectives. 2000;108:701–708
  26. Adlercreutz H. Phytoestrogens and breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 2002;83:113–118
  27. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Research. 2004;6:119–127
  28. Grace PB, Taylor JI, Low YL, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiology Biomarkers Prevention. 2004;13:698–708
  29. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis. 1995;16:2833–2840
  30. Murrill WB, Brown NM, Zhang JX, et al. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis. 1996;17:1451–1457
  31. Constantinou AI, Mehta RG, Vaughan A. Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Research. 1996;16:3293–3298
  32. Lamartiniere CA. Timing of exposure and mammary cancer risk. Journal of the Mammary Gland Biology and Neoplasia. 2002;7:67–76
  33. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Research. 1998;58:3833–3838
  34. Allred CD, Allred KF, Yu YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Research. 2001;61:5045–5050
  35. Darbre PD. Environmental contaminants in milk: the problem of organochlorine xenobiotics. Biochemical Society Transactions. 1998;26:106–112
  36. Nesaretnam K, Hales E, Sohail M, et al. 3,3′,4,4′-Tetrachlorobiphenyl can enhance DMBA-induced mammary carcinogenesis in the rat. European Journal of Cancer. 1998;34:389–393
  37. Desaulniers D, Leingartner K, Russo J, et al. Modulatory effects of neonatal exposure to TCDD, or a mixture of PCBs, p,p′-DDT, and p,p′-DDE, on methylnitrosourea-induced mammary tumor development in the rat. Environmental Health Perspectives. 2001;109:739–747
  38. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disrupters. Environmental Health Perspectives. 2003;111:389–394
  39. Acevedo R, Parnell PG, Villanueva H, et al. The contribution of hepatic steroid metabolism to serum estradiol and estriol concentrations in nonylphenol treated MMTVneu mice and its potential effects on breast cancer incidence and latency. Journal of Applied Toxicology. 2005;25:339–353
  40. Hardell L, Lindstrom G, Liljegren G, et al. Increased concentrations of octachlorodibenzo-p-dioxin in cases with breast cancer—results from a case-control study. European Journal of Cancer Prevention. 1996;5:351–357
  41. Guttes S, Failing K, Neumann K, et al. Chlororganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant breast disease. Archives of Environmental Contamination and Toxicology. 1998;35:140–147
  42. Stellman SD, Djordjevic MV, Muscat JE, et al. Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. Cancer Epidemiology Biomarkers Prevention. 1998;7:489–496
  43. Holford TR, Zheng T, Mayne ST, et al. Joint effects of nine polychlorinated biphenyl (PCB) congeners on breast cancer risk. International Journal of Epidemiology. 2000;29:975–982
  44. Stellman SD, Djordjevic MV, Britton JA, et al. Breast cancer risk in relation to adipose concentrations of organochlorine pesticides and polychlorinated biphenyls in Long Island, New York. Cancer Epidemiology Biomarkers Prevention. 2000;9:1241–1249
  45. Muscat JE, Britton JA, Djordjevic MV, et al. Adipose concentrations of organochlorine compounds and breast cancer recurrence in Long Island, New York. Cancer Epidemiology Biomarkers Prevention. 2003;12:1474–1478
  46. Petreas M, She J, Brown FR, et al. High body burden of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) in California women. Environmental Health Perspectives. 2003;111:1175–1179
  47. Petreas M, Smith D, Hurley S, et al. Distribution of persistent, lipid-soluble chemicals in breast and abdominal adipose tissues: lessons learned from a breast cancer study. Cancer Epidemiology Biomarkers Prevention. 2004;13:416–424
  48. Ibarluzea JM, Fernandez MF, Santa-Marina L, et al. Breast cancer risk and the combined effect of environmental estrogens. Cancer Causes and Control. 2004;15:591–600
  49. Sonawane BR. Chemical contaminants in human milk: an overview. Environmental Health Perspectives. 1995;103:197–205
  50. Solomon GM, Weiss PM. Chemical contaminants in breast milk: time trends and regional variability. Environmental Health Perspectives. 2002;110:A339–A347
  51. Schecter A, Pavuk M, Papke O, et al. Polybrominated ethers (PBDEs) in US mother's milk. Environmental Health Perspectives. 2003;111:1723–1729
  52. Kalantzi OI, Martin FL, Thomas GO, et al. Different levels of polybrominated diphenyl ethers (PBDEs) and chlorinated compounds in breast milk from two UK regions. Environmental Health Perspectives. 2004;112:1085–1091
  53. LaKind JS, Wilkins A, Berlin CM. Environmental chemicals in human milk: a review of levels, infant exposures and health, and guidance for future research. Toxicology and Applied Pharmacology. 2004;198:184–208
  54. Massart F, Harrell JC, Federico G, Saggese G. Human breast milk and xenoestrogen exposure: a possible impact on human health. Journal of Perinatology. 2005;25:282–288
  55. Hoyer AP, Grandjean P, Jorgensen T, et al. Organochlorine exposure and risk of breast cancer. The Lancet. 1998;352:1816–1820
  56. Charlier C, Albert A, Herman P, et al. Breast cancer and serum organochlorine residues. Occupational and Environmental Medicine. 2003;60:348–351
  57. Krieger N, Wolff MS, Hiatt RA, et al. Breast cancer and serum organochlorines: a prospective study among white, black and Asian women. Journal of the National Cancer Institute. 1994;86:589–599
  58. Helzlsouer KJ, Alberg AJ, Huang HY, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiology Biomarkers Prevention. 1999;8:525–532
  59. Wolff MS, Zeleniuch-Jacquotte A, Dublin N, Toniolo P. Risk of breast cancer and organochlorine exposure. Cancer Epidemiology Biomarkers Prevention. 2000;9:271–277
  60. Gammon MD, Wolff MS, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. II organochlorine compound levels in blood. Cancer Epidemiology Biomarkers Prevention. 2002;11:686–697
  61. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer. 1953;6:963–968
  62. Ellsworth DL, Ellsworth RE, Love B, et al. Outer breast quadrants demonstrate increased levels of genomic instability. Annals of Surgical Oncology. 2004;11:861–868
  63. Ellsworth DL, Ellsworth RE, Liebman MN, et al. Genomic instability in histologically normal breast tissues: implications for carcinogenesis. The Lancet Oncology. 2004;5:753–758
  64. Lane-Claypon JE. A further report on cancer of the breast with special reference to its associated antecedent conditions. Reports on Public Health and Medical Subjects no 32. London: Ministry of Health; 1926.
  65. Haagensen CD. Diseases of the breast. 2nd edn. Philadelphia: W.B. Saunders; 1971;
  66. Azzena A, Zen T, Ferrara A, et al. Risk factors for breast cancer. European Journal of Gynaecological Oncology. 1994;15:386–392
  67. Mirick DK, Davis S, Thomas DB. Antiperspirant use and the risk of breast cancer. Journal of the National Cancer Institute. 2002;94:1578–1580
  68. McGrath KG. An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. European Journal of Cancer Prevention. 2003;12:479–485
  69. Bilimoria MM, Winchester DJ, Sener SF, et al. Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Annals of Surgical Oncology. 1999;6:200–207
  70. Darbre PD. Aluminium, antiperspirants and breast cancer. Journal of Inorganic Biochemistry. 2005;99:1912–1919
  71. Lieberman MW, Lykissa ED, Barrios R, et al. Cyclosiloxanes produce fatal liver and lung damage in mice. Environmental Health Perspectives. 1999;107:161–165
  72. Ciniglia C, Cascone C, Giudice RL, et al. Application of methods for assessing the geno- and cytotoxicity of triclosan to C. ehrenbergii. Journal of Hazardous Materials. 2005;122:227–232
  73. Elder RL. Final report on the safety assessment of methylparaben, ethylparaben, propylparaben and butylparaben. Journal American College Toxicology. 1984;3:147–209
  74. Darbre PD, Aljarrah A, Miller WR, et al. Concentrations of parabens in human breast tumours. Journal of Applied Toxicology. 2004;24:5–13
  75. Routledge EJ, Parker J, Odum J, et al. Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic. Toxicology and Applied Pharmacology. 1998;153:12–19
  76. Blair RM, Fang H, Branham WS, et al. The estrogen receptor binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicological Sciences. 2000;54:138–153
  77. Hossaini A, Larsen JJ, Larsen JC. Lack of oestrogenic effects of food preservatives (parabens) in uterotropic assays. Food and Chemical Toxicology. 2000;38:319–323
  78. Jin-Sung P, Lee BJ, Kang KS, et al. Hormonal effects of several chemicals in recombinant yeast, MCF7 cells and uterotropic assays in mice. Microbiology and Biotechnology. 2000;10:293–299
  79. Nishihara T, Nishikawa JI, Kanayama T, et al. Estrogenic activities of 517 chemicals by yeast two-hybrid assay. Journal of Health Science. 2000;46:282–298
  80. Pedersen KL, Pedersen SN, Christiansen LB, et al. The preservatives ethyl-, propyl-, and butylparaben are oestrogenic in an in vivo fish assay. Pharmacology and Toxicology. 2000;86:110–113
  81. Fang H, Tong W, Shi LM, et al. Structure–activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chemical Research in Toxicology. 2001;14:280–294
  82. Okubo T, Yokoyama Y, Kano K, Kano I. ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERα and PR. Food and Chemical Toxicology. 2001;39:1225–1232
  83. Byford JR, Shaw LE, Drew MGB, et al. Oestrogenic activity of parabens in MCF7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 2002;80:49–60
  84. Darbre PD, Byford JR, Shaw LE, et al. Oestrogenic activity of isobutylparaben in vitro and in vivo. Journal of Applied Toxicology. 2002;22:219–226
  85. Darbre PD, Byford JR, Shaw LE, et al. Oestrogenic activity of benzylparaben. Journal of Applied Toxicology. 2003;23:43–51
  86. Lemini C, Jaimez R, Avila ME, et al. In vivo and in vitro estrogen bioactivities of alkyl parabens. Toxicology and Industrial Health. 2003;19:69–79
  87. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758
  88. Jones PS, Thipgen D, Morrison JL, Richardson AP. p-Hydroxybenzoic acid esters as preservatives. III. The physiological disposition ofp-hydroxybenzoic acid and its esters. Journal of American Pharmactists Assocation Science Education. 1956;45:265–273
  89. Heim F, Leuschner F, Wunderlich G. Metabolism of p-hydroxybenzoic acid ethyl ester. Klinische Wochenschr. 1957;35:823–825
  90. Tsukamoto H, Terada S. Metabolism of drugs. XXIII. Metabolic fate of p-hydroxybenzoic acid and its derivatives in rabbits. Chemical and Pharmaceutical Bulletion (Tokyo). 1960;8:1066–1070
  91. Tsukamoto H, Terada S. Metabolism of drugs. XXVI. Metabolic fate of p-hydroxybenzoic acid and its derivatives in rabbits. Chemical and Pharmaceutical Bulletion (Tokyo). 1962;10:86–90
  92. Tsukamoto H, Terada S. Metabolism of drugs. XLVII. Metabolic fate of p-hydroxybenzoic acid and its derivatives in rabbits. Chemical and Pharmaceutical Bulletion (Tokyo). 1964;12:765–769
  93. Derache R, Gourdon J. Metabolism of a food preservative: p-hydroxybenzoic acid and its esters. Food Cosmet Toxicology. 1963;1:189–195
  94. Phillips JC, Topp CS, Gangolli SD. The metabolism of ethyl and n-propyl-p-benzoate (‘parabens’) in male cats. Toxicology Letters. 1978;2:137–142
  95. Kiwada H, Awazu S, Hanano M. The study on the biological fate of paraben at the dose of practical usage in rat. I. The metabolism and excretion of ethyl-p-hydroxybenzoate (ethylparaben) and p-hydroxybenzoic acid. Journal of Pharmacobio Dynamics. 1979;2:356–364
  96. Whitworth CW, Jun HW. Influence of polysorbate 20 and sodium cholate on uptake of p-hydroxybenzoates by the frog, Rana pipens. Journal of Pharmaceutcial Science. 1973;62:1890–1891
  97. Fischmeister I, Hellgren L, Vincent J. Infrared spectroscopy for tracing of topically applied ointment vehicles and active substances on healthy skin. Archives Dermatological Ressearch. 1975;253:63–69
  98. Komatsu H, Suzuki M. Percutaneous absorption of butylparaben through guinea pig skin in vitro. Journal of Pharmaceutcial Science. 1979;68:596–598
  99. Kitigawa S, Li H, Sato S. Skin permeation of parabens in excised guinea pig dorsal skin, its modification by penetration enhancers and their relationship with n-octanol/water partition coefficients. Chemical and Pharmaceutical Bulletion (Tokyo). 1997;45:1354–1357
  100. Bando H, Mohri S, Yamashita F, et al. Effects of skin metabolism on percutaneous penetration of lipophilic drugs. Journal of Pharmaceutcial Science. 1997;86:759–761
  101. Lobemeier C, Tschoetschel C, Westie S, Heymann E. Hydrolysis of parabenes by extracts from differing layers of human skin. Biological Chemistry. 1996;377:647–651
  102. Jeffrey AM, Williams GM. Letters to the editor. Journal of Applied Toxicology. 2004;24:301–303
  103. Flower C. Letters to the editor. Journal of Applied Toxicology. 2004;24:304–305
  104. Klopman G, Chakravarti SK. Screening of high production volume chemicals for estrogen receptor binding activity (II) by the MultiCASE expert system. Chemosphere. 2003;51:461–468
  105. Pugazhendhi D, Pope GS, Darbre PD. Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines. Journal of Applied Toxicology. 2005;25:301–309
  106. Lemini C, Silva G, Timossi C, et al. Estrogenic effects of p-hydroxybenzoic acid in CD1 mice. Environmental Research. 1997;75:130–134
  107. Soni MG, Carabin IG, Burdock GA. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food and Chemical Toxicology. 2005;43:985–1015
  108. Bergfeld WF, Belsito DV, Marks JG, Andersen FA. Safety of ingredients used in cosmetics. Journal of the American Acadmican of Dermatology. 2005;52:125–132
  109. Laden K, Felger CB. Antiperspirants and deodorants. Cosmetic Science and Technology Series. vol. 7. New York: Marcel Dekker; 1988;
  110. Habs H, Simon B, Thiedemann KU, Howe P. Aluminium. Environmental Health Criteria. 1997;194
  111. Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacology and Toxicology. 2001;88:159–167
  112. In:  Exley C editors. Aluminium and Alzheimer's Disease: The Science that Describes the Link. London: Elsevier; 2001;
  113. Anane R, Bonini M, Grafeille JM, Creppy EE. Bioaccumulation of water soluble aluminium chloride in the hippocampus after transdermal uptake in mice. Archives of Toxicology. 1995;69:568–571
  114. Anane R, Bonini M, Creppy EE. Transplacental passage of aluminium from pregnant mice to fetus organs after maternal transcutaneous exposure. Human and Experimental Toxicology. 1997;16:501–504
  115. Flarend R, Bin T, Elmore D, Hem SL. A preliminary study of the dermal absorption of aluminium from antiperspirants using aluminium-26. Food and Chemical Toxicology. 2001;39:163–168
  116. Flarend R. In:  Exley C editors. Aluminium and Alzheimer's Disease: The Sscience that Describes the Link. London: Elsevier; 2001;p. 75–95
  117. Guillard O, Fauconneau B, Olichon D, et al. Hyperaluminemia in a woman using an aluminium-containing antiperspirant for 4 years. The American Journal of Medicine. 2004;117:956–959
  118. Exley C. Aluminium in antiperspirants: more than just skin deep. The American Journal of Medicine. 2004;117:969–970
  119. Predki PF, Sarkar B. Effect of replacement of ‘zinc finger’ zinc on estrogen receptor DNA interactions. Journal of Biological Chemistry. 1992;267:5842–5846
  120. Stoica BSKatzenellenbogen, Martin MB. Activation of estrogen receptor-α by the heavy metal cadmium. Molecular Endocrinology. 2000;14:545–553
  121. Stoica EPentecost, Martin MB. Effects of arsenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. Endocrinology. 2000;141:3595–3602
  122. Stoica E, Stoica E Pentecost, Martin MB. Effects of selenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. Journal of Cellular Biochemistry. 2000;79:282–292
  123. Martin MB, Reiter R, Pham T, et al. Estrogen-like activity of metals in Mcf-7 breast cancer cells. Endocrinology. 2003;144:2425–2436
  124. Johnson MD, Kenney N, Stoica A, et al. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nature Medicine. 2003;9:1081–1084
  125. Nair B, Elmore AR. Final report on the safety assessment of stearoxy dimethicone, dimethicone, methicone, amino bispropyl dimethicone, aminopropyl dimethicone, amodimethicone, amodimethicone hydroxystearate, behenoxy dimethicone, C24-28 alkyl methicone, C30-45 alkyl methicone, C30-45 alkyl dimethicone, cetearyl methicone, cetyl dimethicone, dimethoxysilyl ethylenediaminopropyl dimethicone, hexyl methicone, hydroxypropyldimethicone, stearamidopropyl dimethicone, stearyl dimethicone, stearyl methicone and vinyldimethicone. International Journal of Toxicology. 2003;22:11–35
  126. Luu HMD, Hutter JC. Bioavailability of octamethylcyclotetracyclosiloxane (D4) after exposure to silicones by inhalation and implantation. Environmental Health Perspectives. 2001;109:1095–1101
  127. Hayden JF, Barlow SA. Structure–activity relationships of organosiloxanes and the female reproductive system. Toxicology and Applied Pharmacology. 1972;21:68–79
  128. McKim JM, Wilga PC, Breslin WJ, et al. Potential estrogenic and antiestrogenic activity of the cyclic siloxane ocatamethylcyclotetrasiloxane (D4) and the linear siloxane hexamethyldisiloxane (HMDS) in immature rats using the uterotrophic assay. Toxicological Sciences. 2001;63:37–46
  129. He B, Rhodes-Brower S, Miller MR, et al. Octamethylcyclotetrasiloxane exhibits estrogenic activity in mice via ERα. Toxicology and Applied Pharmacology. 2003;192:254–261
  130. Zareba G, Gelein R, Morrow PE, Utell MJ. Percutaneous absorption studies of octamethylcyclotetrasiloxane using the human skin/nude mouse model. Skin Pharmacology and Applied Skin Physiology. 2002;15:184–194
  131. Kala SV, Lykissa ED, Neely MW, Lieberman MW. Low molecular weight silicones are widely distributed after a single subcutaneous injection in mice. The American Journal of Pathology. 1998;152:645–649
  132. Messager S, Goddard PA, Dettmar PW, Maillard JY. Determination of the antibacterial efficacy of several antiseptics tested on skin by an ‘ex-vivo’ test. Journal of Medical Microbiology. 2001;50:284–292
  133. Liu B, Wang Y, Fillgrove KL, Anderson VE. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemotherapy and Pharmacology. 2002;49:187–193
  134. Foran CM, Bennett ER, Benson WH. Developmental evaluation of a potential non-steroidal estrogen: triclosan. Marine Environmental Research. 2000;50:153–156
  135. Houtman CJ, Van Oostveen AM, Brouwer A, et al. Identification of estrogenic compounds in fish bile using bioassay-directed fractionation. Environmental Science and Technology. 2004;38:6415–6423
  136. Hovander L, Malmberg T, Athanasiadou M, et al. Identification of hydroxylated PCB metabolites and other phenolic halogenated pollutants in human blood plasma. Archives of Environmental Contamination and Toxicology. 2002;42:105–117
  137. Adolfsson-Erici M, Petersson M, Parkkonen J, Sturve J. Triclosan, a commonly used bacteriocide found in human milk and in the aquatic environment in Sweden. Chemosphere. 2002;46:1485–1489
  138. Schlumpf M, Cotton B, Conscience M, et al. In vitro and in vivo estrogenicity of UV screens. Environmental Health Perspectives. 2001;109:239–244
  139. Nagtegaal M, Ternes TA, Baumann W, Nagel R. UV-Filtersubstanzen in Wasser und Fischen. UWSF-Z Umweltchem Okotox. 1997;9:79–86
  140. Treffel P, Gabard B. Skin penetration and sun protection factor of ultraviolet filters from two vehicles. Pharmaceutical Research. 1996;13:770–774
  141. Hayden CGJ, Roberts MS, Bensen HAE. Systemic absorption of sunscreen after topical application. The Lancet. 1997;350:863–864
  142. Felix T, Hall BJ, Brodbelt JS. Determination of benzophenone-3 and metabolites in water and human urine by solid-phase microextraction and quadrupole ion trap GC-MS. Analytica Chimica Acta. 1998;371:195–203
  143. Hany J, Nagel R, Nachweis V. UV-Filtersubstanzen in muttermilch. Deutsche Lebensmittel-Rundshau. 1995;91:341–345
  144. Koda T, Umezu T, Kamata R, et al. Uterotrophic effects of benzophenone derivatives and a p-hydroxybenzoate used in ultraviolet screens. Environmental Research. 2005;98:40–45
  145. Inui M, Adachi T, Takenaka S, et al. Effect of UV screens and preservatives on vitellogenin and choriogenin production in male medaka (Oryzias latipes). Toxicology. 2003;194:43–50
  146. Houligan J, Brody C, Schwan B. Phthalates, beauty products and the FDA. http://www.nottoopretty.org/images/Not Too Pretty_final.pdf.
  147. Jobling S, Reynolds T, White R, et al. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environmental Health Perspectives. 1995;103:582–587
  148. Harris CA, Henttu P, Parker MG, Sumpter JP. The estrogenic activity of phthalate esters in vitro. Environmental Health Perspectives. 1997;105:802–811
  149. Okubo T, Suzuki T, Yokoyama Y, et al. Estimation of estrogenic and anti-estrogenic aactivities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro. Biological and Pharmaceutical Bulletin. 2003;26:1219–1224
  150. Calafat AM, Slakman AR, Silva MJ, et al. Automated solid phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences. 2004;805:49–56
  151. Gomez E, Pilon A, Fenet H, et al. Estrogenic activity of cosmetic components in reporter cell lines: parabens, UV screens and musks. Journal of Toxicology and Environmental Health Part A. 2005;68:239–251
  152. Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorganic and Medicinal Chemistry Letters. 2001;11:1839–1842
  153. Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. The Lancet. 1999;353:1742–1745
  154. Rimsten A. Symptoms and signs in benign and malignant tumours of the breast. Upsala Journal of Medical Sciences. 1976;81:54–60
  155. Stebbing JF, Nash AG. Diagnosis and management of phyllodes tumour of the breast: experience of 33 cases at a specialist centre. Annals of the Royal College of Surgeons of England. 1995;77:181–184
  156. Parsons WH. Cancer of the Breast. Oxford: Blackwell Scientific Publications; 1959;
  157. Rajapakse N, Butterworth M, Kortenkamp A. Detection of DNA strand breaks and oxidised DNA bases at a single-cell level resulting from exposure to estradiol and hydroxylated metabolites. Environmental and Molecular Mutagenesis. 2005;45:397–404
  158. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer. The Lancet Oncology. 2004;5:174–181
  159. Hall JM, Korach KS. Analysis of the molecular mechanisms of human estrogen receptors α and β reveals differential specificity in target promoter regulation by xenoestrogens. Journal of Biological Chemistry. 2002;277:44455–44461

PII: S1521-690X(05)00074-6

doi: 10.1016/j.beem.2005.09.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 121-143 , March 2006

Article Tools

* Image Usage & Resolution